Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) is projected to release its Q1 2025 earnings data after the market closes on Tuesday, May 13th. Analysts expect Capricor Therapeutics to post earnings of ($0.33) per share and revenue of $3.16 million for the quarter.
Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last issued its quarterly earnings data on Wednesday, March 19th. The biotechnology company reported ($0.16) EPS for the quarter, topping analysts' consensus estimates of ($0.31) by $0.15. Capricor Therapeutics had a negative net margin of 146.86% and a negative return on equity of 112.95%. The business had revenue of $11.13 million during the quarter, compared to analysts' expectations of $9.87 million. On average, analysts expect Capricor Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Capricor Therapeutics Trading Down 8.9 %
Shares of NASDAQ:CAPR traded down $0.62 during trading on Friday, reaching $6.35. The company's stock had a trading volume of 3,630,166 shares, compared to its average volume of 1,607,844. Capricor Therapeutics has a 12 month low of $3.52 and a 12 month high of $23.40. The firm's 50 day simple moving average is $11.16 and its two-hundred day simple moving average is $14.23. The stock has a market capitalization of $290.05 million, a PE ratio of -5.99 and a beta of 0.85.
Wall Street Analysts Forecast Growth
Several research firms recently weighed in on CAPR. HC Wainwright restated a "buy" rating and set a $77.00 price target on shares of Capricor Therapeutics in a report on Monday, March 17th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $30.00 price target on shares of Capricor Therapeutics in a research note on Thursday, March 20th. One analyst has rated the stock with a sell rating and six have given a buy rating to the company's stock. Based on data from MarketBeat, Capricor Therapeutics has an average rating of "Moderate Buy" and an average target price of $34.50.
View Our Latest Report on Capricor Therapeutics
About Capricor Therapeutics
(
Get Free Report)
Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
Further Reading
Before you consider Capricor Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Capricor Therapeutics wasn't on the list.
While Capricor Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
